We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Vanda Pharmaceuticals Inc | NASDAQ:VNDA | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.02 | -0.40% | 4.99 | 4.50 | 5.40 | 5.08 | 4.87 | 5.00 | 1,384,022 | 05:00:08 |
From May 2022 to May 2024
By Sabela Ojea
Vanda Pharmaceuticals Inc. said Tuesday that it has sued the U.S. government for allegedly sharing trade secrets and confidential information related to two of its medications.
The biopharmaceutical company alleged the U.S. Food and Drug Administration improperly provided confidential details from its sleep-wake disorder drug Hertlioz and schizophrenia treatment Fanapt to generic drug manufacturers as it reviewed the company's new drug applications.
The lawsuit seeks an award of economic damages, the company said, noting that it was filed in the U.S. Court of Federal Claims.
Fanapt and Tasimelteon were approved by the FDA in 2009 and 2014, respectively.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
May 02, 2023 13:28 ET (17:28 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Vanda Pharmaceuticals Chart |
1 Month Vanda Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
